Adaptimmune has more good news from its SPEAR T-cell therapy, yesterday unveiling encouraging early results in four patients with myxoid/round ... a rare sarcoma. The trial reported three partial ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Nina Axelrad Keynote Address: Soft-Tissue Sarcoma: 25 Years of Achievements ... the differentiation of different types of liposarcomas (myxoid, round cell, pleomorphic). These pathologists ...
LV-305 is under clinical development by Merck and currently in Phase I for Synovial Sarcoma. According to GlobalData, Phase I drugs for Synovial Sarcoma have a 76% phase transition success rate (PTSR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback